Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $6.19M | $3.61M | $2.19M |
| Revenue growth | — | — | — | — | — | -41.7% | -39.5% |
| Operating income | -$54.0M | -$97.8M | -$128M | -$97.6M | -$88.1M | -$89.2M | -$88.0M |
| Operating margin | — | — | — | — | -1423.5% | -2469.0% | -4024.9% |
| Net income | -$52.3M | -$109M | -$128M | -$96.0M | -$87.7M | -$131M | -$24.2M |
| Net margin | — | — | — | — | -1416.2% | -3633.6% | -1106.7% |
| EPS (diluted) | -$26.04 | -$10.87 | -$3.22 | -$2.25 | -$34.20 | -$20.94 | -$2.45 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$46.8M | -$74.3M | -$116M | -$79.4M | -$79.0M | -$80.7M | -$82.5M |
| Capital expenditures | $2.79M | $2.06M | $892K | $943K | $19.0K | $130K | — |
| Free cash flow | -$49.6M | -$76.3M | -$117M | -$80.3M | -$79.0M | -$80.9M | — |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $69.6M | $220M | $187M | $81.3M | $136M | $37.0M | $18.3M |
| Total assets | $147M | $265M | $235M | $147M | $152M | $70.1M | $88.5M |
| Total liabilities | $29.3M | $45.3M | $50.6M | $42.8M | $59.4M | $99.1M | $35.0M |
| Shareholders' equity | -$64.9M | $220M | $185M | $104M | $92.1M | -$29.0M | $53.5M |
| Retained earnings | -$66.2M | -$175M | -$303M | -$399M | -$487M | -$618M | -$642M |
| Shares (wtd avg diluted) | 3.93M | 38.1M | 42.7M | 42.7M | 2.56M | 6.26M | 9.88M |
Every figure is extracted from Aligos Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.